EGFR and non-small cell lung carcinoma: CheckMate 722 evaluates Nivolumab in addition to chemotherapy to Ipilimumab or chemotherapy alone in NSCLC patients with EGFR mutations who have failed first- or second-line EGFR TKI therapy (NCT02864251) [104].